The clinical manifestations and survival of systemic lupus erythematosus patients in Turkey: Report from two centers

Lupus

Volumn 22, Issue 13, 2013, Pages 1416-1424

  Pamuk, O N ^a   Akbay, F G ^b   Donmez S ^a   Yilmaz, N ^b   Calayir, G B ^a   Yavuz, S ^b  

^a TRAKYA UNIVERSITY   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

nephritis; prognosis; survival; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ARTHRITIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CAUSE OF DEATH; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DISCOID LUPUS ERYTHEMATOSUS; DRY EYE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIVEDO RETICULARIS; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NEUROLOGIC DISEASE; PHOTOSENSITIVITY; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SEPSIS; SLEDAI; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TURKEY (REPUBLIC); XEROSTOMIA;

NEPHRITIS; PROGNOSIS; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CAUSE OF DEATH; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TURKEY;

EID: 84887071646     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313499956     Document Type: Article

References (31)

1. Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by SLE. J Chronic Dis. 1955 ; 1: 12-32
2. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol. 1997 ; 24: 1061-1065
3. Souza DC, Santo AH, Sato EI. Mortality profile related to systemic lupus erythematosus: A multiple cause-of-death analysis. J Rheumatol. 2012 ; 39: 496-503
4. Danila MI, Pons-Estel GH, Zhang J, Vila LM, Reveille JD, Alarcon GS. Renal damage is the most important predictor of mortality within the damage index: Data from LUMINA LXIV. A multiethnic US cohort. Rheumatology. 2009 ; 48: 542-545
5. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 ; 54: 2550-2557
6. Urowitz MB, Gladman DD, Tom BD, Ibañez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol. 2008 ; 35: 2152-2158
7. McCarty DJ, Manzi S, Medsger TA, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum. 1995 ; 38: 1260-1270
8. Fernández M, Alarcón GS, Calvo-Alén J, et al. A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis Rheum. 2007 ; 57: 576-584
9. Cooper GS, Parks CG, Treadwell EL, et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus. 2002 ; 11: 161-167
10. Flower C, Hennis AJ, Hambleton IR, Nicholson GD, Liang MH. Barbados National Lupus Registry Group. Systemic lupus erythematosus in an African Caribbean population: incidence, clinical manifestations, and survival in the Barbados National Lupus Registry. Arthritis Care Res (Hoboken). 2012 ; 64: 1151-1158
11. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
13. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 ; 353: 2550-2558
14. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 ; 106: 3143-3421
15. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. 1: Diagnosis and classification of diabetes mellitus, 2 ed. Geneva: World Health Organization, 1999. WHO/NCD/NCS/99. Geneva: World Health Organization ; 1999:
16. World Health Organization. Global database on body mass index: BMI classification. http://apps.who.int/bmi/index.jsp?introPage=intro-3.html (2009).
17. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
18. Mok CC, To CH, Ho LY, Yu KL. Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. J Rheumatol. 2008 ; 35: 1978-1982
19. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G. Incidence studies of systemic lupus erythematosus in southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol. 2000 ; 27: 685-691
20. Rabbani MA, Siddiqui BK, Tahir MH, et al. Systemic lupus erythematosus in Pakistan. Lupus. 2004 ; 13: 820-825
21. Ippolito A, Petri M. An update on mortality in systemic lupus erythematosus. Clin Exp Rheumatol. 2008 ; 26: S72 - S79
22. Alonso MD, Llorca J, Martinez-Vazquez F, et al. Systemic lupus erythematosus in northwestern Spain: A 20-year epidemiologic study. Medicine (Baltimore). 2011 ; 90: 350-358
23. Smith PP, Gordon C. Systemic lupus erythematosus: Clinical presentations. Autoimmun Rev. 2010 ; 10: 43-45
24. Mialdea M, Sangle SR, D'Cruz DP. Antiphospholipid (Hughes) syndrome: Beyond pregnancy morbidity and thrombosis. J Autoimmune Dis. 2009 ; 6: 3-3
25. Barón MA, Khamashta MA, Hughes GR, D'Cruz DP. Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: Preliminary data. Ann Rheum Dis. 2005 ; 64: 144-146
26. Ames PR, Antinolfi I, Scenna G, Gaeta G, Margaglione M, Margarita A. Atherosclerosis in thrombotic primary antiphospholipid syndrome. J Thromb Haemost. 2009 ; 7: 537-542
27. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: Preliminary data. Ann Rheum Dis. 2005 ; 64: 315-317
28. Margarita A, Batuca J, Scenna G, et al. Subclinical atherosclerosis in primary antiphospholipid syndrome. Ann N Y Acad Sci. 2007 ; 1108: 475-480
29. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003 ; 349: 2399-2406
30. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. Semin Arthritis Rheum 2013. [Epub ahead of print] DOI: 10.1016/j.semarthrit.2012.12.002.
31. Skaggs BJ, Hahn BH, McMahon M. Accelerated atherosclerosis in patients with SLE-mechanisms and management. Nat Rev Rheumatol. 2012 ; 8: 214-223